The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment

Gut. 2014 Mar;63(3):515-24. doi: 10.1136/gutjnl-2013-304472. Epub 2013 May 11.

Abstract

Objective: There is evidence that natural killer (NK) cells help control persistent viral infections including hepatitis C virus (HCV). The phenotype and function of blood and intrahepatic NK cells, in steady state and after interferon (IFN) α treatment has not been fully elucidated.

Design: We performed a comparison of NK cells derived from blood and intrahepatic compartments in multiple paired samples from patients with a variety of chronic liver diseases. Furthermore, we obtained serial paired samples from an average of five time points in HCV patients treated with IFNα.

Results: Liver NK cells demonstrate a distinct activated phenotype compared to blood manifested as downregulation of the NK cell activation receptors CD16, NKG2D, and NKp30; with increased spontaneous degranulation and IFN production. In contrast, NKp46 expression was not downregulated. Indeed, NKp46-rich NK populations were the most activated, correlating closely with the severity of liver inflammation. Following initiation of IFNα treatment there was a significant increase in the proportion of intrahepatic NK cells at days 1 and 3. NKp46-rich NK populations demonstrated no reserve activation capacity with IFNα treatment and were associated with poor viral control on treatment and treatment failure.

Conclusions: NKp46 marks out pathologically activated NK cells, which may result from a loss of homeostatic control of activating receptor expression in HCV. Paradoxically these pathological NK cells do not appear to be involved in viral control in IFNα-treated individuals and, indeed, predict slower rates of viral clearance.

Keywords: CHRONIC VIRAL HEPATITIS; HEPATITIS C; IMMUNE-MEDIATED LIVER DAMAGE; IMMUNOLOGY IN HEPATOLOGY.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use*
  • Biomarkers / metabolism
  • Biopsy
  • Case-Control Studies
  • Drug Administration Schedule
  • Drug Resistance, Viral / immunology*
  • Drug Therapy, Combination
  • Female
  • Flow Cytometry
  • Hepatic Insufficiency / blood
  • Hepatic Insufficiency / drug therapy
  • Hepatic Insufficiency / immunology
  • Hepatic Insufficiency / pathology
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / immunology
  • Hepatitis C, Chronic / pathology
  • Humans
  • Immunohistochemistry
  • Interferon-alpha / therapeutic use*
  • Killer Cells, Natural / metabolism*
  • Linear Models
  • Liver / immunology*
  • Liver / pathology
  • Liver / virology
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Natural Cytotoxicity Triggering Receptor 1 / metabolism*
  • Ribavirin / therapeutic use
  • Severity of Illness Index
  • Treatment Failure
  • Viral Load

Substances

  • Antiviral Agents
  • Biomarkers
  • Interferon-alpha
  • NCR1 protein, human
  • Natural Cytotoxicity Triggering Receptor 1
  • Ribavirin